Novel targeted agents for the treatment of bladder cancer: translating laboratory advances into clinical application
Bladder cancer is a common and frequently lethal cancer. Natural history studies indicate two distinct clinical and molecular entities corresponding to invasive and non-muscle invasive disease. The high frequency of recurrence of noninvasive bladder cancer and poor survival rate of invasive bladder...
Main Authors: | Xiaoping Yang, Thomas W. Flaig |
---|---|
Format: | Article |
Language: | English |
Published: |
Sociedade Brasileira de Urologia
2010-06-01
|
Series: | International Brazilian Journal of Urology |
Subjects: | |
Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382010000300003 |
Similar Items
-
Efficacy of Osimertinib Combined with Bevacizumab in Advanced Non-small Cell
Lung Cancer Patients with Acquired EGFR T790M Mutation
by: Yanfei GU, et al.
Published: (2022-12-01) -
Role of FGF System in Neuroendocrine Neoplasms: Potential Therapeutic Applications
by: Giovanni Vitale, et al.
Published: (2021-04-01) -
Microvascularization and Expression of Fibroblast Growth Factor and Vascular Endothelial Growth Factor and Their Receptors in the Mare Oviduct
by: Pedro Pinto-Bravo, et al.
Published: (2021-04-01) -
Salivary Vascular Endothelial Growth Factor and Epidermal Growth Factor Levels in Patients with Recurrent Aphthous Stomatitis: a Meta-Analysis
by: Paria Motahari, et al.
Published: (2023-09-01) -
New Directions and Challenges in Targeted Therapies of Advanced Bladder Cancer: The Role of FGFR Inhibitors
by: Katarzyna Szklener, et al.
Published: (2022-03-01)